Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Tanta, Egypt
Rheumatology and Health Services Research, The University of Sheffield, Sheffield, UK.
Ann Rheum Dis. 2023 Dec;82(12):1508-1510. doi: 10.1136/ard-2023-224315. Epub 2023 Jul 19.
Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology.
生物类似药是指与参照生物制品高度相似的产品。在非洲，许多国家仍在制定生物类似药批准的监管框架，目前风湿性疾病的生物类似药也很少。在非洲使用生物类似药为用生物药物治疗更多的风湿病患者提供了一个重要的机会。本文旨在阐述在非洲风湿病中使用生物类似药的潜在益处、挑战和当前的努力。
